-transparent.png){kind=logo}
Cyclophosphamide, mitoxantrone, fluorouracil versus conventional CMF as adjuvant treatment in node-positive breast cancer patients. A Hellenic Cooperative Oncology Group Study. 1996
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
1st Department of Internal Medicine, Oncology Section, AHEPA Hospital, Aristotle University, Thessaloniki, Greece.
362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p=0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment.
Related Publications
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
August 2001,
American journal of clinical oncology,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
October 1998,
European journal of cancer (Oxford, England : 1990),
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
October 2002,
American journal of clinical oncology,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
January 1985,
Neoplasma,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
April 1993,
International journal of oncology,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
January 2002,
Anticancer research,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
December 1998,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
January 2010,
Breast cancer research and treatment,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
June 2008,
Cancer investigation,
G Fountzilas, and
A Polichronis, and
K Katsohis, and
K Gennatas, and
D Toussis, and
D Skarlos, and
P Kosmidis, and
S Vassilaros, and
C Semoglou, and
T Giannakakis, and
E Fahantidis, and
G Klouvas, and
N Tsavaris, and
C Konstantaras, and
P Makrantonakis, and
C Kolotas, and
N Zamboglou, and
S Tsiliakos, and
D Hainoglou, and
N Mylonakis, and
N Pavlidis
March 1993,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
